Fate Therapeutics (FATE) EPS (Basic) (2016 - 2025)
Historic EPS (Basic) for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$0.27.
- Fate Therapeutics' EPS (Basic) rose 3250.0% to -$0.27 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.33, marking a year-over-year increase of 1939.39%. This contributed to the annual value of -$1.7 for FY2024, which is 351.01% down from last year.
- According to the latest figures from Q3 2025, Fate Therapeutics' EPS (Basic) is -$0.27, which was up 3250.0% from -$0.29 recorded in Q2 2025.
- In the past 5 years, Fate Therapeutics' EPS (Basic) ranged from a high of -$0.19 in Q1 2023 and a low of -$0.86 during Q3 2022
- Moreover, its 5-year median value for EPS (Basic) was -$0.47 (2024), whereas its average is -$0.49.
- As far as peak fluctuations go, Fate Therapeutics' EPS (Basic) skyrocketed by 7205.88% in 2023, and later plummeted by 14736.84% in 2024.
- Over the past 5 years, Fate Therapeutics' EPS (Basic) (Quarter) stood at -$0.72 in 2021, then grew by 19.44% to -$0.58 in 2022, then grew by 22.41% to -$0.45 in 2023, then fell by 13.13% to -$0.51 in 2024, then surged by 46.96% to -$0.27 in 2025.
- Its EPS (Basic) was -$0.27 in Q3 2025, compared to -$0.29 in Q2 2025 and -$0.32 in Q1 2025.